Taibang Biologic Group Secures Equity Raising of US$300 Million

Taibang Biologic Group (previously listed as China Biologic Products Holdings, Inc. on the Nasdaq under the trading symbol “CBPO”) (the “Group”) entered into definitive transaction documents for equity raising of US$300 million with a group of investors led by Platinum Orchid, a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), and GIC. China Life and Cinda Kunpeng are participating in this financing round as co-investors.

This is Taibang Biologic Group’s first equity financing transaction since the completion of its privatization in April 2021 by a consortium led by Centurium Capital. The Group has received strong interests from top-tier international and domestic investors, which reflects the capital markets’ high recognition of the Group's ability to deliver clinical benefits to patients and create value for shareholders.

This round of financing will further optimize the Group’s capital structure, which will help solidify its leading position in the domestic market and attract more stable and extensive resources to support the expansion of plasma stations and the research and development of new products, thereby allowing the Group to achieve more rapid and sustainable growth in the China market.

Founded in 2002, the Group is a leading Chinese biopharmaceutical company that provides a comprehensive range of plasma products, principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products, or plasma products, in China. The Group possesses plasma manufacturing sites with leading technology standards and world-class R&D capabilities and plasma product laboratories. The Group has a strong product portfolio covering 10 approved plasma products with over 20 different dosage forms across 3 main categories: human albumin, human immunoglobulin, and human coagulation factors. In addition, the Group also operates a non-plasma products business segment with a number of products such as placental polypeptides, artificial dura mater, artificial nerve sheath, and aponeurosis, as well as a full line of products in the field of neurosurgery under the German brand named Zeppelin. The Group’s products are sold in the vast majority of the provincial medical markets in mainland China. For more information on the Group, please visit: https://www.chinabiologic.com/

About ADIA
Established in 1976, the Abu Dhabi Investment Authority (ADIA) is a globally-diversified investment institution that prudently invests funds on behalf of the Government of Abu Dhabi through a strategy focused on long-term value creation. For more information on ADIA, please visit: https://www.adia.ae.

About GIC
GIC is a leading global investment firm established in 1981 to secure Singapore’s financial future. As the manager of Singapore’s foreign reserves, GIC takes a long-term, disciplined approach to investing and is uniquely positioned across a wide range of asset classes and active strategies globally. These include equities, fixed income, real estate, private equity, venture capital and infrastructure. Its long-term approach, multi-asset capabilities and global connectivity enable it to be an investor of choice. GIC seeks to add meaningful value to its investments. Headquartered in Singapore, GIC has a global talent force of over 1,900 people in 11 key financial cities and has investments in over 40 countries. For more information on GIC, please visit: www.gic.com.sg.

About China Life
China Life Private Equity Investment (“China Life”) is a professional private equity investment platform under China Life. With the investment philosophy of prospect for the future, embrace innovation and create value, China Life Private Equity Investment has made extensive investment layout in the fields of life science, medical technology, medical services and digital healthcare, and has invested in a number of industry-leading medical and healthcare companies in China.

About Cinda Kunpeng
Founded in April 2019, Cinda Kunpeng (Shenzhen) Investment Management Co., Ltd. (“Cinda Kunpeng”) is an investment management firm focusing on mergers and acquisitions, as well as investment in strategic emerging industries in the Guangdong-Hong Kong-Macao Greater Bay Area, creating incremental value by empowering the enterprises in the industries. Cinda Kunpeng mainly participates in equity investments in area of mergers and acquisitions and reorganizations related to listed and pre-IPO companies, providing enterprises with necessary funds, and cooperating with the enterprises in mergers and acquisitions of high-quality assets in the industries. The Merger and Acquisition Fund managed by Cinda Kunpeng focuses on investing in the strategic emerging industries encouraged by the government, mainly including advanced manufacturing, healthcare, and new-generation information technology. Its mission is to promote the transformation and upgrade of real economy in the Guangdong-Hong Kong-Macao Greater Bay Area (including Shenzhen), so as to create incremental value for its investments. Cinda Kunpeng targets to achieve win-win results through specialization and cooperation, resource integration with industry partners, and create a healthy ecosystem to facilitate the development of real economy.